Pulmonary surfactant lines the airway epithelium and creates a potential barrier to successful transfection of the epithelium in vivo. Based on the functional properties of pulmonary surfactant protein B (SP-B) and the fact that this protein is neither toxic nor immunogenic in the airway, we hypothesized that SP-B could be modified to deliver DNA to airway cells. We have modified native bovine SP-B by the covalent linkage of poly(lysine) (average molecular mass of 3. 
that the conformation of [Lys] 1Oua.-SP-B was comprised primarily of a-helical structure compared with a predominately aggregated structure of unmodified poly(lysine). We conclude that poly(lysine) conjugates of SP-B effectively deliver DNA in vitro and may have utility as DNA delivery vehicles to the airway in vivo.
With the successful cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) cDNA and correction of the cAMP-dependent chloride transport defect by transfection ofcells, strategies to transfect pulmonary cells in vitro and in vivo are rapidly being developed with the goal of gene therapy of cystic fibrosis and other pulmonary diseases. Such corrective therapies are approachable in lung disease since noninvasive access to the epithelial surface of the organ is possible by conventional instillation or aerosolization technologies. Successful transfection of airway cells in vitro and in vivo reported in recent literature includes the use of viruses with specific tropism for airway epithelial cells but also other compounds not indigenous to the airway. To date these include replication-defective adenoviral vectors, adenoassociated viral vectors, cationic liposomes including Lipofectin and N-[1-(2,3-dioleyloxy)propyl]-N,NN-trimethylammonium, and protein-cationic peptide complexes (1) (2) (3) (4) (5) (6) (7) (8) . Recently, Curiel and associates (5) have applied the strategy of Wu and associates (4) to link poly(lysine) covalently to a cell surface receptor ligand to deliver DNA to lung cells via the receptor'endosomal pathway. Specifically, Curiel et al. (5) have shown that DNA complexed to poly(lysine) conjugates of the transferrin receptor was taken up and expressed by epithelial cells. The process was enhanced by coupling the ligand-DNA complex with adenovirus through an antibody or mixing the ligand-DNA with adenovirus (7) . Recently, adenovirus complexed directly with poly(lysine) was shown to deliver DNA effectively in vivo (8) .
Pulmonary surfactant is a complex mixture comprised predominately of lipids with about 10% protein by weight. Pulmonary surfactant overlays the proximal and distal epithelium that forms the logical target cells for gene therapy of cystic fibrosis and potentially other pulmonary diseases. One of the critical protein components of surfactant is surfactantassociated protein B (SP-B). SP-B, which exhibits surface tension-lowering properties, is a component of various surfactant preparations used in the treatment of neonatal respiratory distress syndrome. Surfactant preparations have been shown to be nonimmunogenic and nontoxic when used in the therapy of respiratory distress syndrome (9) . Due to its compatibility with surfactant and potential safety, SP-B may be useful in gene therapy strategies that require repetitive treatment of the airway necessary to achieve adequate or consistent levels of gene expression.
SP-B in its mature form is a nonglycosylated 79-amino acid polypeptide generated by translation of a 2.0-kb mRNA and subsequent proteolytic processing of an -39-kDa primary translation product as determined by sequence analysis with cDNA clones and direct amino acid sequence analysis (10) (11) (12) (13) (14) . SP-B mRNA and protein are expressed at high levels in bronchiolar and alveolar epithelium.
Recently, Breslin and Weaver (15) showed that exogenous SP-B, in the absence or presence of isolated rat surfactant, is taken up by airway cells in vitro and found in endosomes, through a process that does not appear to be receptor mediated. Using competition assays with unlabeled and al. (16) demonstrated that uptake of SP-B by pulmonary type II cells was unsaturable. However, in the presence of surfactant phospholipids, the uptake of SP-B was saturable. These data led Bates et al. (16) to conclude that SP-B, in the absence of phospholipids, exists primarily as aggregates, and the mechanism of cellular uptake may be dependent on the physical state of the SP-B molecule. The intracellular fate of SP-B is not completely resolved, although it may be recycled to lamellar bodies. SP-B and several synthetic peptides of SP-B enhance phospholipid uptake and inhibit phospholipid secretion by type II epithelial cells in vitro and, therefore, may play an important role in recycling of surfactant in the alveolus (17) . In addition, SP-B has been shown to promote fusion of membranes (18)-a property of SP-B that may play a role in its reuptake in type II cells.
In the present study, we provide evidence that poly(lysine) conjugates of SP-B are effective in delivering DNA to airway cells in culture. The modified forms of SP-B were preferentially linked at the N terminus with poly(lysine). The modified SP-B exhibited an increase in a-helical content compared to unmodified SP-B or unmodified poly(lysine). To determine the potential of these conjugates to deliver and enhance uptake ofDNA in the airway epithelium for gene therapy, we tested the functional expression of test plasmid DNA delivered to cells in culture.
METHODS
Purification of Native SP-B. SP-B, 8.7 kDa (monomeric form), was isolated and purified as described (19) (20) (21) . Minimal linkage of the poly(lysine) to lysine and arginine residues of SP-B was controlled by pH. Purifications of the PDP intermediates and poly(lysine) conjugates of SP-B were performed by size exclusion chromatography using Sephadex G-75 and/or dialysis (cellulose tubing, molecular weight cut-off range of 12,000-14,000).
The degree to which SP-B and poly(lysine) were substituted with 2-pyridyldisulfide residues was determined by first thiolating the PDP intermediates with the addition of dithiothreitol (final concentration, mM EDTA (TE) for 1/2-1 hr at 25TC. For experiments with Lipofectin and Lipofectin-DNA, samples were prepared in polystyrene tubes according to manufacturer's recommendations (GIBCO/BRL). The plasmid, pCPA-RSV, has been described elsewhere and is expressed well when transfected into the pulmonary adenocarcinoma cell line H441 (23 (Fig. 3A) .
To analyze efficiency of transfection, protein-DNA molar ratios were varied and used to transfect H441 cells with complexes formed by varying DNA concentration (Table 1) or protein concentration (Fig. 3B) . The most effective protein-DNA molar ratios yielding maximal CAT conversion in culture were 625:1 (Table 1) or 1000:1 (Fig. 3) (Fig. 3B) . The level of CAT conversion varied with the cell type and the protein-DNA molar ratio used. At a protein*DNA ratio of 250:1, H441 cells showed the highest activity (Fig. 3B, lane 3) , but at 1000:1 HeLa cells showed the greatest activity (Fig. 3B, lane 5 This conformation is also in contrast to that of native (unmodified) SP-B, which is comprised of 50%6 a-helix and 20% ,(3structure (25) . The increase in a-helical content upon formation of [Lys] 1okD-SP-B may enhance binding of DNA to the poly(lysine) moiety of the conjugate, thereby enhancing effective DNA delivery.
We chose SP-B since, unlike transferrin, it is taken up by airway cells in a non-receptor-mediated process through an endosomal pathway (15) , and in an aggregated state (as would (Fig. 3B) . The latter two cell lines would be unlikely to contain a putative SP-B receptor. Thus,
[Lys]1OkD.-SP-B may deliver DNA to the cells through the fusigenic properties of SP-B (18) and through the poly(lysine) moiety, and not exclusively through a specific SP-B receptor.
[Lys],-SP-B conjugates with poly(lysine) chains of an average molecular mass of 10 kDa were more effective than 3.3-kDa poly(lysine) moieties. We hypothesize that a shorter poly(lysine) chain may not allow accessibility of the cationic sites due to steric effects of the protein.
In vitro protein-DNA molar ratios of 500:1 to 1000:1 were most effective for DNA transfection. When 0.5-1.0 nmol of
[Lys]1fDa-SP-B was used, a protein*DNA molar ratio of 2550 Genetics: Baatz et al. 5000:1 or 2500:1 resulted in reduced effectiveness (Table 1) as did ratios <250:1 (Fig. 3) . Agarose gel retardation of protein-DNA migration revealed that aprotein-DNA ratio of at least 250:1 was necessary to completely bind detectable DNA. Since the amount of protein necessary to completely retard DNA is two to four times less than the amount needed for the most efficient CAT activity ( Fig. 3 (26) (27) (28) . Plasmids containing these promoters should be expressed only in epithelial cells. Poly(lysine) alone is not known to be immunogenic (29) and the presence ofcirculating antibodies specific for SP-B was not detected in infants treated with preparations containing bovine SP-B (9) . Since SP-B is a component ofpulmonary surfactant, it is unlikely that surface immunity to this protein will arise. Also, since SP-B is recycled in the airway, it is unlikely that toxic amounts of SP-B will accumulate following repetitive treatment ofthe airway. Therefore, the [Lys]-SP-B conjugates may not be toxic or immunogenic when applied in vivo.
Adenovirus disrupts endosomal membranes through the action ofthe protein capsid (30, 31) . Enhanced uptake through the endocytotic pathway has been shown for ligand-toxin complexes and DNA-protein conjugates in the presence of adenovirus (5, (30) (31) (32) . In the transfections shown in Fig. 4 
